Kardogrel

Clopidogrel Hydrogen Sulfate, the active ingredient in Kardogrel, is an antiplatelet agent presented as an oral formulation for oral use. It reduces the risk of atherothrombotic events in patients with acute coronary syndrome, prior ischemic stroke or transient ischemic attack, and established peripheral arterial disease.

GNH USA supplies Kardogrel as a licensed, GDP‑compliant international pharmaceutical supplier, providing the product to hospitals, pharmacies, clinics and other health‑care institutions worldwide, with adherence to quality standards and regulatory requirements, through reliable logistics and dedicated customer support.

Kardogrel (clopidogrel hydrogen sulfate) is used to reduce thrombotic risk in several cardiovascular and cerebrovascular conditions. - Acute coronary syndrome: helps prevent atherothrombotic events such as myocardial infarction. - Ischemic stroke or transient ischemic attack history: lowers the chance of recurrent stroke. - Peripheral arterial disease: reduces incidence of myocardial infarction and other arterial events. - Post‑myocardial infarction: provides secondary prevention of further cardiovascular events.

Clopidogrel may be associated with a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Bleeding gums: mild oral bleeding that may increase with brushing. - Bruising: easy bruising or petechiae, especially after minor trauma. - Nausea: occasional nausea, sometimes accompanied by mild stomach discomfort.

Serious or Rare Side Effects: - Severe bleeding: gastrointestinal or intracranial hemorrhage that may be life‑threatening. - Thrombocytopenia: a marked reduction in platelet count, increasing bleeding risk. - Allergic reactions: rash, pruritus, or anaphylaxis requiring immediate medical attention. - Liver enzyme elevation: increased ALT/AST indicating possible hepatic irritation. - Neutropenia: reduced neutrophil count that may predispose to infection.

When prescribing Kardogrel, clinicians should consider several precautionary measures to ensure safe use. - Assess bleeding risk: evaluate patient history of hemorrhage before initiating therapy. - Monitor platelet count: regular checks are advised during treatment. - Adjust in renal impairment: dose may need modification in severe kidney disease. - Caution in hepatic disease: use carefully in patients with liver dysfunction. - Avoid in hypersensitivity: discontinue if allergic reaction occurs. - Store at ambient temperature: keep below 25 °C in original packaging, protect from moisture.

Clopidogrel interacts with several medicines; awareness of these interactions helps prevent reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Proton pump inhibitors (omeprazole, esomeprazole): may diminish clopidogrel activation. - Strong CYP2C19 inhibitors (fluoxetine, fluconazole): reduce conversion to active metabolite. - Anticoagulants (warfarin, direct oral anticoagulants): increase bleeding risk.

Moderate Interactions (Monitor Closely): - NSAIDs (ibuprofen, naproxen): additive bleeding potential. - SSRIs/SNRIs (sertraline, venlafaxine): may increase hemorrhagic risk. - Statins (atorvastatin, simvastatin): potential for enhanced antiplatelet effect.